Table 5.

Differential Protection Against Vaccine-Serotype Carriage Endpoints

Serotype	Vaccine	Reduction, Per Dose Received	DR and MR Per Dose Received, %
		Estimate (95% CI)	Reference serotypes 1, 5, 6A, 7F, and 19A		Reference serotype 3
			DR (95% CI)a	MR (95% CI)b	DR (95% CI)a	MR (95% CI)b
PCV7 serotypes	PCV7/13	30 (22–37)	10 (−5 to 26)	12 (−7 to 28)	84 (35–144)	53 (33–68)
Serotypes 1, 5, 6A, 7F, 19A	PCV13 only	19 (5–32)	…	…	74 (23–135)	46 (22–64)
Serotype 3	PCV13 only	−55 (−115 to −5)	−74 (−135 to −23)	−93 (−179 to −28)	…	…

Vaccine effectiveness estimates are calculated as 1-mOR times 100%. The mORs are calculated from the relative odds of receipt of vaccine doses (defined as a continuous variable) among case children versus matched controls.

Abbreviations: CI, confidence interval; DR, difference in reduction; mOR, matched odds ratio; MR, marginal reduction; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.

^aDR, per dose received, was estimated as $(1-{\theta }_i)-(1-{\theta }_j)$ for a comparison of the magnitude of protection against endpoints i and j.

^bMR, per dose received, was estimated as $1{-}^{{\theta }_i}\text{}╱\text{}{\text{}}_{{\theta }_j}$ to quantify the additional protection conferred against endpoint i beyond protection conferred against endpoint j.